Ascites
Drug research and approvals for ascites: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 49 studies of ascites are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 0 approved and 3 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 49
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 49 recruiting on ClinicalTrials.gov ↗- Optimal Treatment Strategy for Spontaneous Bacterial PeritonitisNCT07923318 · Not applicable · Chonnam National University Hospital · starts Oct 4, 2026
- At-Home Paracentesis for Cancer-Related Malignant Ascites (Paracentesis)NCT07490626 · Not applicable · University of Utah · starts Sep 15, 2026
- To Develop and Validate an Equation for Determination of Major Adverse Kidney Events in Patients With Decompensated…NCT07794787 · Not reported · Institute of Liver and Biliary Sciences, India · starts Aug 31, 2026
- TLR9 Immunotherapy for Peritoneal CarcinomatosisNCT07658196 · Phase 1 · Brown University · starts Aug 25, 2026
- Gut Leakage' in DengueNCT07602920 · Not reported · University of Oxford · starts Aug 1, 2026
- VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)NCT07390344 · Not reported · W.L.Gore & Associates · starts Jul 20, 2026
- "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized…NCT07684326 · Phase 2 / Phase 3 · Beni-Suef University · starts Jul 1, 2026
- Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced…NCT07855640 · Not reported · Zhejiang Cancer Hospital · starts Jul 1, 2026
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With CirrhosisNCT07322237 · Phase 4 · Post Graduate Institute of Medical Education and Research, Chandigarh · starts Apr 1, 2026
- Apixaban-PK Trial: Preventing Portal Hypertension Complications in CirrhosisNCT07521332 · Phase 4 · Asian Institute Of Medical Sciences · starts Apr 1, 2026
Drug Pipeline
2 approved, 4 in phase 3, 7 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Catumaxomab, Spironolactone
- Albumin human
- Phase 3 Bilirubin sequestering agent
- Satavaptan
- Phase 3 Vasopressin V2 receptor antagonist
- Propranolol
- Phase 3 Beta-1 adrenergic receptor antagonist
- Midodrine
- Phase 3 Adrenergic receptor alpha-1 agonist
- Bevacizumab
- Phase 2 Vascular endothelial growth factor A inhibitor
- Serplulimab
- Phase 2 Programmed cell death protein 1 antagonist
- Metformin
- Phase 2 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Sunitinib
- Phase 2 Macrophage colony stimulating factor receptor inhibitor
- Empagliflozin
- Phase 2 Sodium/glucose cotransporter 2 inhibitor
- Rivoceranib
- Phase 2 Vascular endothelial growth factor receptor 2 inhibitor
- Etilefrine
- Phase 2
- Tislelizumab
- Phase 1 Programmed cell death protein 1 inhibitor
- Molgramostim
- Phase 1
How Its Trials Ended
252 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 69 whose ending is known, 30% met their primary endpoint, 6% missed it and 64% stopped early.
- Completed, result not reported7329%
- Status unknown5723%
- Ongoing5321%
- Stopped: other or unclear3012%
- Met its primary endpoint218%
- Stopped: enrollment or feasibility104%
- Missed its primary endpoint42%
- Stopped: lack of efficacy21%
- Stopped: safety10%
- Stopped: sponsor or business decision10%
FDA Orphan Designations
Approved first, then open designations, newest first| Dec 14, 2023 | [Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln…Treatment of ascites due to all etiologies except cancer | Ocelot Bio, Inc. | Designated |
| Apr 14, 2020 | DocarpamineTreatment of ascites due to all etiologies except cancer | Martin Pharmaceuticals, Inc. | Designated |
| Sep 8, 2016 | TerlipressinTreatment of ascites due to all etiologies except cancer | Bio Vie Inc. | Designated |
Medicines Authorised in the EU
Newest first| Feb 10, 2025 | KorjunyCatumaxomab | Atnahs Pharma Netherlands B.V. | EMA ↗ |
| May 26, 2023 | QaialdoSpironolactone | Lipomed GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA